Published in Pharmacogenetics on March 01, 2002
Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol (2004) 1.58
CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. PLoS One (2015) 1.40
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
Applications of CYP450 testing in the clinical setting. Mol Diagn Ther (2013) 1.08
Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol (2010) 0.99
Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol (2003) 0.99
Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol (2013) 0.98
Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals (Basel) (2010) 0.97
Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther (2010) 0.95
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol (2005) 0.94
Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol (2003) 0.91
Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol (2008) 0.89
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol (2007) 0.87
Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol (2013) 0.86
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol (2008) 0.86
Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol (2011) 0.85
Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol (2006) 0.81
Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice. AAPS J (2009) 0.80
Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing. Expert Rev Cardiovasc Ther (2010) 0.79
A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study. Br J Clin Pharmacol (2004) 0.79
Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. Eur J Clin Pharmacol (2011) 0.78
Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. Eur J Clin Pharmacol (2005) 0.78
CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response. Pharmacogenetics (2002) 0.78
CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol (2011) 0.78
Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies? PPAR Res (2015) 0.77
Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol (2005) 0.76
Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of Gujarat. Indian J Pharm Sci (2014) 0.75
CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients. J Diabetes Investig (2016) 0.75
Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity. Eur J Clin Pharmacol (2005) 0.75
A Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa Japan. PLoS One (2016) 0.75
Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes (2016) 0.75
Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med (2003) 3.89
Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndrome. Nat Genet (2010) 3.60
Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke (2007) 2.76
Terminally differentiated CD8⁺ T cells negatively affect bone regeneration in humans. Sci Transl Med (2013) 2.43
Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One (2008) 2.39
Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics (2006) 2.07
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation (2005) 1.87
Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther (2005) 1.83
Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood (2003) 1.76
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol (2002) 1.75
Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem (2005) 1.74
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol (2002) 1.73
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics (2003) 1.63
Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol (2004) 1.58
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
Endothelin-1 gene variant Lys198Asn and plasma endothelin level in obstructive sleep apnea. Cardiology (2008) 1.47
Genome-wide single-nucleotide polymorphism arrays demonstrate high fidelity of multiple displacement-based whole-genome amplification. Electrophoresis (2005) 1.45
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther (2004) 1.43
Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis (2007) 1.42
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant (2004) 1.42
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther (2002) 1.42
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos (2002) 1.40
Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke (2006) 1.39
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet (2005) 1.36
Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? Nat Rev Drug Discov (2005) 1.35
CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis (2003) 1.28
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res (2013) 1.27
The GA octodinucleotide repeat binding factor BBR participates in the transcriptional regulation of the homeobox gene Bkn3. Plant J (2003) 1.26
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol (2008) 1.26
No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One (2010) 1.25
Parallel multigrid preconditioner for the cardiac bidomain model. IEEE Trans Biomed Eng (2004) 1.21
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc Natl Acad Sci U S A (2002) 1.18
Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care (2009) 1.16
The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem (2004) 1.16
Repulsive guidance molecule-A (RGM-A) inhibits leukocyte migration and mitigates inflammation. Proc Natl Acad Sci U S A (2011) 1.15
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem (2005) 1.14
Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl) (2008) 1.14
Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos (2008) 1.14
Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics (2008) 1.12
Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol (2013) 1.11
Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol (2008) 1.11
Regulatory T cells accumulate and proliferate in the ischemic hemisphere for up to 30 days after MCAO. J Cereb Blood Flow Metab (2012) 1.11
Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies. Pharmacogenomics (2010) 1.10
Altered cell-mediated immunity and increased postoperative infection rate in long-term alcoholic patients. Anesthesiology (2004) 1.09
Immune responses after acute ischemic stroke or myocardial infarction. Int J Cardiol (2010) 1.08
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther (2006) 1.07
Reduced-order preconditioning for bidomain simulations. IEEE Trans Biomed Eng (2007) 1.07
An unusual internal ribosomal entry site of inverted symmetry directs expression of a potato leafroll polerovirus replication-associated protein. Proc Natl Acad Sci U S A (2003) 1.06
AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit (2006) 1.04
Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain (2009) 1.03
Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant (2003) 1.03
Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics (2008) 1.02
Implicit motives and gonadal steroid hormones: effects of menstrual cycle phase, oral contraceptive use, and relationship status. Horm Behav (2003) 1.02
Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells. Exp Dermatol (2007) 1.02
Influence of stroke localization on autonomic activation, immunodepression, and post-stroke infection. Cerebrovasc Dis (2011) 1.01
Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples. Transplantation (2009) 1.01
Human peripheral blood and bone marrow Epstein-Barr virus-specific T-cell repertoire in latent infection reveals distinct memory T-cell subsets. Eur J Immunol (2010) 1.01
Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther (2009) 1.01
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol (2002) 0.99
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet (2004) 0.99
Standardized immune monitoring for the prediction of infections after cardiopulmonary bypass surgery in risk patients. Cytometry B Clin Cytom (2003) 0.99
Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2004) 0.99
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther (2006) 0.99
CCN1: a novel inflammation-regulated biphasic immune cell migration modulator. Cell Mol Life Sci (2012) 0.98
Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem Res Toxicol (2006) 0.98
Validity of PCR with emphasis on variable number of tandem repeat analysis. Clin Biochem (2002) 0.97
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. MAbs (2013) 0.97
Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ). J Clin Psychopharmacol (2002) 0.96
Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene (2006) 0.96
Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther (2004) 0.96
Immunodepression after aneurysmal subarachnoid hemorrhage. Stroke (2010) 0.96
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol (2004) 0.95
Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol (2006) 0.95
A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. Cancer Epidemiol Biomarkers Prev (2003) 0.95
Different modes of IL-10 and TGF-beta to inhibit cytokine-dependent IFN-gamma production: consequences for reversal of lipopolysaccharide desensitization. J Immunol (2003) 0.95